Prespecified analysis demonstrates altered bleeding risk with abelacimab in atrial fibrillation based on anticoagulation history, indicating clinical relevance.
This prespecified analysis from AZALEA-TIMI 71 demonstrated that prior oral anticoagulation (OAC) experience modifies bleeding risk in atrial fibrillation. The factor XI inhibitor abelacimab consistently reduced bleeding irrespective of prior OAC experience, with potentially greater absolute benefit among OAC-naïve patients.
No takes yet. Share an insight, caveat, or question.
Small et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: